Medical and Science
Budget forecasts must be realistic about a COVID-19 vaccine
Medical News: Next week’s Federal Budget must be based on the reality that the world is at least a year away from a broad roll out of a COVID-19 vaccine, and not on optimistic forecasts that the global economy is about to return to business as usual, the nation’s leading medical association has warned.
The AMA has released a communique from its most recent Federal Council meeting, held on 26 September, which was dominated by the global pandemic.
“We have seen different strategies adopted by different States and Territories, with differing results,” AMA President, Dr Omar Khorshid, said.
“What we need to see now is national leadership, that ensures that all Australians understand the challenges that we are facing as a nation, and one single strategy that will lead us all out of this pandemic. This is how we get back to normal.”
Dr Khorshid said that, while there is optimism that one of the 150-plus vaccines and treatments in trial around the world might succeed, it will be some time before any of them are widely available.
The Commonwealth must continue its work to identify a suite of promising vaccine candidates and negotiate access to these as part of a strategy to ensure that Australia is able to access a successful vaccine(s) in a timely fashion. The Commonwealth’s participation in COVAX to support developing nations in accessing vaccines/treatments is also welcome.
The Commonwealth, along with the states and territories, needs to develop a plan to support the timely roll out of a vaccine(s), with input from key stakeholders including general practice.
“Governments and the community must also contemplate the potential scenario where a vaccine is not found, and the available treatments continue to offer supportive care as opposed to a cure,” Dr Khorshid said.
“We know from the Spanish Flu that this might mean living with the virus for two to three years before the pandemic comes to an end, although we still have much to learn about COVID-19 and its long term impact.”
The overseas evidence shows countries with an effective public-health response that controls the spread of COVID-19 builds community confidence, and this results in better economic outcomes. There is no “trade-off” between public health and economic activity, as those places that are harder hit by the pandemic are experiencing even more significant economic consequences. The Reserve Bank has stated that the future path of the recovery is highly dependent on containment of the virus.
The Australian Health Protection Principal Committee (AHPPC) has provided strong national leadership, giving expert advice to guide our COVID-19 response. The processes and advice of the AHPPC need to be more transparent, backed by agreement that all jurisdictions will implement AHPPC advice, except in situations where local circumstances and corresponding medical evidence dictate otherwise.
Dr Khorshid said that the Federal Government had acted quickly to protect the economy through the JobKeeper and increased JobSeeker payments, and there is the very likely possibility that these will need to be maintained for longer than currently planned to protect workers and businesses while the threat of the virus exists.
“The JobSeeker Coronavirus supplement has helped people to survive very difficult economic times, and the Commonwealth must now consider a permanent increase to the rate of JobSeeker,” Dr Khorshid said.
“This support must remain in place for a number of years, recognising not only the impact of COVID-19, but also unemployment and social dislocation that will be a feature of our economic recovery.”
News & Trends - Pharmaceuticals
Roche’s immunotherapy drug shows promising results for Australian patients with rare blood cancer
Pharma News: Roche’s immunotherapy drug has shown high response rates in patients with a rare form of blood cancer that […]
MoreNews & Trends - Pharmaceuticals
Government seals deal with industry for rare cancer therapy
Pharma News: Australian children and young adults diagnosed with high-risk neuroblastoma will continue to receive free access to a promising, […]
MoreNews & Trends - MedTech & Diagnostics
Abbott showcases leadless pacemaker system to local stakeholders
MedTech & Diagnostics News: Leadless pacemakers are promising alternatives to transvenous pacing. Abbott hosted a stakeholder event at the recent […]
MoreNews & Trends - Pharmaceuticals
Australian scientists pivotal in new drug class from BMS
Pharma News: The first new class of drug for schizophrenia in decades has been approved, offering a fresh approach by […]
More